Deadline for Pfizer's tender offer for King extended

NEW YORK Pfizer has extended the deadline of its $3.6 billion offer to buy King Pharmaceuticals, Pfizer said Monday.

Pfizer said it had extended its tender offer to Dec. 17 because certain conditions had not been met, but the two companies plan to have it finished by the end of this year or the beginning of next year.

King, based in Bristol, Tenn., specializes in branded opioid prescription painkillers.